

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Colorectal cancer (update)

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No additional equality issues were identified by stakeholders during consultation.

Older people were raised by a stakeholder as a specific group, however, this was already recognised before the development of this guideline and has been considered throughout. The committee considered that rather than age, performance status and comorbidities (which may be linked to older age) are potentially important determinants of treatment decision making and information sharing. Evidence based on either age, performance status or comorbidities was sought for several evidence reviews but no evidence stratified by these characteristics was identified and no recommendations based on these characteristics were made.

The protocols in appendix A in the evidence reviews outline where subgroup analysis based on age, performance status or comorbidities were planned, although due to lack of such evidence no such subgroup analyses were done. This has also been highlighted in the evidence reports' "The Committee's discussion of the evidence" section where relevant.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, any changes made to the recommendation have no effect on equalities considerations.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, none of the changes made to the recommendation have an impact on people with disabilities.

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in question 4.2, or otherwise fulfil NICE's obligations to advance equality?

None of the changes made to the recommendation have an effect on equalities considerations.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

The equality considerations are addressed under the "The Committee's discussion of the evidence" section of evidence reviews:

- C5 Effectiveness of exenterative surgery for locally advanced or recurrent rectal cancer
- D4 Local and systemic treatments for metastatic colorectal cancer isolated in the peritoneum
- E3 Information needs of people prior, during and after treatment for colorectal cancer.

4.5 Have the Committee's considerations of equality issues been described in the final guideline, and, if so, where?

The guideline highlights the importance of tailoring information provision and discussions about treatment options and side effects to individual needs and circumstances. A cross-reference the NICE guidelines on [patient experience in adult NHS services](#) and [decision-making and mental capacity](#) were included because the committee recognises that some people with colorectal cancer may have conditions or comorbidities which may have an impact on their ability to absorb information and make decisions.

The committee agreed that the guideline would improve and standardise access to best available treatment and fulfil NICE's obligations to advance equality.

Updated by Developer Maija Kallioinen (Guideline lead)

Date 25/10/2019

Approved by NICE quality assurance lead Simon Ellis

Date 13/01/2020